Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant925 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04689178 | Cervical Cancer Screening Uptake: A Randomised Controlled Trial Assessing the Effect of Sending Invitation Letters to Nonadherent Women(IMPACTGP) | unknown | N/A | 195,000 | Nantes University HospitalOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05287048 | Evaluation of MCM5 in Postmenopausal Bleeding Patients | unknown | — | 2,000 | Arquer Diagnostics LtdINDUSTRY | 1 | Feb 1, 2023 |
| clinicaltrials |
| NCT05707312 | Staging Endometrial caNcer Based on molEcular ClAssification | unknown | — | 1,032 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT04704908 | Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m) | unknown | — | 979 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT04969445 | The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 647 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05045755 | The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female | unknown | — | 1,339 | Jun ZhangOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05634798 | An Observational Study Based on Endometrial Cancer Risk Screening Model | unknown | — | 2,000 | Peking Union Medical College HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05446883 | QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | unknown | Phase 3 | 498 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05334303 | The Impact of Epigenetic MMRd in Endometrial carcinomas-a Real World Study | unknown | — | 400 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Nov 21, 2022 | clinicaltrials |
| NCT03049553 | Trial23 - A Method Study on Cervical Screening in Women Offered HPV-vaccination as Girls | unknown | N/A | 7,000 | University of CopenhagenOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT05602831 | Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer | unknown | — | 108 | Fudan UniversityOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05595252 | Retrospective Study on the Evolution of CIN 1 to 3 in Per and Postpartum in Nancy From 2014 to 2022 | unknown | — | 100 | Central Hospital, Nancy, FranceOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05588076 | Endometrial Lesions Predictions | unknown | — | 900 | Beijing Friendship HospitalOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05531981 | Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer | unknown | — | 350 | Peking Union Medical College HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05437692 | Zimberelimab Combined With Concurrent Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 19 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569200 | The Clinical Trial About Treatment of Benign Uterus Myoma by Haifu Focused Ultrasound Tumor Therapeutic System | unknown | N/A | 10 | National Taiwan University HospitalOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05570331 | Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women | unknown | — | 2,200 | Ding MaOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT05561413 | Gynaecology Exercise and Mindfulness Study(GEMS) | unknown | N/A | 40 | University of UlsterOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT05560035 | The Effect of Intravenous Lidocaine on THBS2 and Angiogenic Factors Expression in Women Undergoing Cervical Cancer Surgery | unknown | N/A | 60 | General Hospital of Ningxia Medical UniversityOTHER | 0 | Sep 29, 2022 | clinicaltrials |
| NCT05557565 | A Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Cervical Cancer | unknown | Phase 2 | 150 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05536843 | Clinical, Translational and Biomarker-Based Female Genital HPV Induced Dysplasia and Cancer Screening Study Using Cf-HPV-DNA Blood Tests(TTMV HPV DNA) | unknown | — | 500 | University of Mississippi Medical CenterOTHER | 0 | Sep 13, 2022 | clinicaltrials |
| NCT05532930 | An Exploratory Study of Using Magnetic Resonance Prognostic Imaging Markers for Radiotherapy In Patients With Cervix Cancer (EMPIRIC Study)(EMPIRIC) | unknown | — | 40 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | Sep 8, 2022 | clinicaltrials |
| NCT04398446 | Effect of Hemp-CBD on Patients With CIPN(Coala-T-CBD) | unknown | Phase 2 | 56 | Main Line HealthOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05142397 | The Dynamic Process of VMB and Mucosal Immunity After FUS Treatment of CIN Patients With Fertility Requirement | unknown | — | 90 | Shufang ChangOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04484415 | Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)(APRICITY) | unknown | Phase 3 | 402 | Asieris MediTech (Hong Kong) Co., Ltd.INDUSTRY | 1 | Aug 12, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT04641728 | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer | unknown | Phase 2 | 28 | Saitama Medical University International Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04995731 | Risk Assessment of Endometrial Hyperplasia and Endometrial Cancer | unknown | — | 328 | Assiut UniversityOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05179317 | Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05475847 | Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer(TIL) | unknown | Phase 1 | 20 | Fudan UniversityOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT04845425 | Analysis of miRNA Expression in Endometrial Cancer(MIRCE) | unknown | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05247619 | A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | unknown | Phase 2 | 49 | Zhejiang Cancer HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05444374 | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 48 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05122221 | CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | unknown | Phase 1 | 12 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT04742543 | Virtual Reality During Conization of Cervix Uterus Under Local Anesthesia | unknown | N/A | 100 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04982146 | Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei | unknown | Phase 1 | 10 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05387460 | Radiomics Based Multimodal Transvaginal Ultrasound Imaging in Endometrial Cancer | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT04772001 | Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer | unknown | N/A | 53 | Zhongnan HospitalOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT02494791 | Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer(LS2) | unknown | N/A | 886 | University Health Network, TorontoOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT04856306 | Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L(Magical) | unknown | — | 300 | Medstar Health Research InstituteOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT04866394 | Stereotactic Pelvic Adjuvant Radiation TherApy in Cancers of the UteruS(SPARTACUS) | unknown | N/A | 40 | Sunnybrook Health Sciences CentreOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05362669 | SMS Messaging for Invitation in the Cervical Cancer Screening Programme(CERCA-SMS) | unknown | N/A | 450 | Institut Català d'OncologiaOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05359913 | Podcasting Cervical Cancer Prevention for AAW | unknown | N/A | 40 | University of HoustonOTHER | 0 | May 4, 2022 | clinicaltrials |
| NCT05342506 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05314907 | Acceptability of Self-sampling for Cervical Cancer Screening | unknown | N/A | 1,614 | Institut d'Investigació Biomèdica de BellvitgeOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05311566 | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | unknown | Phase 2 | 92 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 6, 2023source: clinicaltrials